Evidence map›Paper›PMID 23179933›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2013

Functional variants of MIF, INFG and TFNA genes are not associated with disease susceptibility or hearing loss progression in patients with Ménière's disease.

Irene Gázquez, Antonia Moreno, Teresa Requena, Jeff Ohmen, Sofia Santos-Perez, Ismael Aran, Andres Soto-Varela, Herminio Pérez-Garrigues, Alicia López-Nevot, Angel Batuecas and 3 more

Open access · greenAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. The Impact of Genetic Factors in Ménière's Disease.International journal of molecular sciences · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. The genetics of Ménière's disease.The application of clinical genetics · 2015
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 2 countries.

Irene GázquezOtology and Neurotology Group CTS495, Centro de Genómica e Investigación Oncológica Pfizer-Universidad de Granada-Junta de Andalucía (GENyO), Avda. de la Ilustración, 114, 18014 Granada, Spain.
Antonia Moreno
Teresa Requena
Jeff Ohmen
Sofia Santos-Perez
Ismael Aran
Andres Soto-Varela
Herminio Pérez-Garrigues
Alicia López-Nevot
Angel Batuecas
Rick A Friedman
Miguel A López-Nevot
Jose A López-Escamez
Hospital Universitario Virgen de las Nieves · ESComplexo Hospitalario Universitario A Coruña · ESHouse Clinic · USPfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research · ESComplejo Hospitalario de Pontevedra · ESComplejo Hospitalario de Salamanca · ESHospital de Poniente · ESLeitat Technological Center · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Variability in acute immune response genes could determine susceptibility or prognosis for Ménière's disease (MD). The cytokines tumor necrosis factor α (TNFα), macrophage migration inhibitory factor (MIF) and interferon γ (INFγ) are proinflammatory cytokines of the innate immune response. These cytokines mediate inflammation and have been previously associated with the inflammatory process in several autoimmune diseases. We investigated the association between functional allelic variants of MIF (rs35688089), IFNG (rs2234688) and TNFA (rs1800629) in patients with MD. In addition to testing these variants for an association with disease, we also tested for an association with clinical aspects of disease progression, such as persistence of vertigo and the sensorineural hearing loss. A total of 580 patients with diagnosis of definite MD, according to the diagnostic scale of the American Academy of Otolaryngology-Head and Neck Surgery, and 552 healthy controls were included. DNA samples from a set of 291 American patients were used to confirm the results obtained in the MIF gene in our Spanish cohort. Although we found a significant association with the allele containing five repeats of CATT within the MIF gene in patients with MD in the Spanish cohort [corrected p = 0.008, OR = 0.69 (95 % CI, 0.54-0.88)], this finding could not be replicated in the American set. Moreover, no genetic associations for variants in either the TNFA or IFNG genes and MD were found. These results support the conclusion that functional variants of MIF, INFG, and TFNA genes are not associated with disease susceptibility or hearing loss progression in patients with MD.

Indexed as

AdolescentAdultAgedAged, 80 and overAllelesCohort StudiesCross-Cultural ComparisonDisease ProgressionFemaleGenetic Association StudiesGenetic Predisposition to DiseaseHearing Loss, SensorineuralHumansInterferon-gammaIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsInterferon-gammainterferon gamma (1-39)Intramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMIF protein, humanPeptide FragmentsTumor Necrosis Factor-alpha

Identifiers

PMID23179933
OpenAlexW1990099495

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.